Moxifloxacin for community-acquired pneumonia.
作者信息
Rijnders Bart J A
出版信息
Antimicrob Agents Chemother. 2003 Jan;47(1):444; author reply 444-5. doi: 10.1128/AAC.47.1.444-445.2003.
Abstract
摘要
相似文献
1
Moxifloxacin for community-acquired pneumonia.莫西沙星用于社区获得性肺炎。
Antimicrob Agents Chemother. 2003 Jan;47(1):444; author reply 444-5. doi: 10.1128/AAC.47.1.444-445.2003.
2
Gatifloxacin and moxifloxacin: two new fluoroquinolones.
Med Lett Drugs Ther. 2000 Feb 21;42(1072):15-7.
3
Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.莫西沙星：微生物学、药理学、临床及安全性特征综述
Expert Opin Pharmacother. 2001 Feb;2(2):317-35. doi: 10.1517/14656566.2.2.317.
4
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.口服莫西沙星在社区获得性肺炎标准一线治疗中的有效性。
Eur Respir J. 2003 Jan;21(1):135-43. doi: 10.1183/09031936.03.00045202.
5
[Playing it safe in bronchopulmonary infections].[在支气管肺部感染中采取保守治疗]
MMW Fortschr Med. 2003 May 1;145(18):57.
6
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.莫西沙星：社区获得性呼吸道感染治疗中临床应用潜力综述
Drugs. 2000 Jan;59(1):115-39. doi: 10.2165/00003495-200059010-00010.
7
Treatment with moxifloxacin versus standard therapy for community-acquired pneumonia.
Clin Infect Dis. 2006 Jul 1;43(1):109; author reply 110-1. doi: 10.1086/504944.
8
A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.莫西沙星治疗呼吸道感染的药物经济学综述
Expert Opin Pharmacother. 2008 Jul;9(10):1735-44. doi: 10.1517/14656566.9.10.1735.
9
An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.与静脉注射/口服阿莫西林克拉维酸联合或不联合克拉霉素相比，序贯静脉注射/口服莫西沙星治疗社区获得性肺炎的经济学评价。
Chest. 2003 Aug;124(2):526-35. doi: 10.1378/chest.124.2.526.
10
Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.德国使用新型8-甲氧基氟喹诺酮类药物莫西沙星治疗社区获得性呼吸道感染的临床经验。
J Int Med Res. 2001 Mar-Apr;29(2):51-60. doi: 10.1177/147323000102900202.
本文引用的文献
1
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.在需要初始肠外治疗的社区获得性肺炎患者中，序贯静脉注射（i.v.）和口服莫西沙星与序贯静脉注射和口服阿莫西林克拉维酸钾（联合或不联合克拉霉素）的随机对照试验。
Antimicrob Agents Chemother. 2002 Jun;46(6):1746-54. doi: 10.1128/AAC.46.6.1746-1754.2002.
2
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.对左氧氟沙星的耐药性与肺炎球菌肺炎治疗失败
N Engl J Med. 2002 Mar 7;346(10):747-50. doi: 10.1056/NEJMoa012122.
3
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.成人社区获得性肺炎管理指南。诊断、严重程度评估、抗菌治疗及预防
Am J Respir Crit Care Med. 2001 Jun;163(7):1730-54. doi: 10.1164/ajrccm.163.7.at1010.
4
Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.获得左氧氟沙星耐药肺炎链球菌的危险因素：一项病例对照研究。
Clin Infect Dis. 2001 Mar 1;32(5):701-7. doi: 10.1086/319222. Epub 2001 Feb 28.
Zotero 插件